Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RIN1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RIN1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RIN1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RIN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006049115 | Prostate | Tumor | regulation of cell projection assembly | 52/3246 | 188/18723 | 2.71e-04 | 2.24e-03 | 52 |
GO:003109915 | Prostate | Tumor | regeneration | 54/3246 | 198/18723 | 3.07e-04 | 2.47e-03 | 54 |
GO:012003215 | Prostate | Tumor | regulation of plasma membrane bounded cell projection assembly | 51/3246 | 186/18723 | 3.87e-04 | 2.99e-03 | 51 |
GO:009917312 | Prostate | Tumor | postsynapse organization | 47/3246 | 168/18723 | 3.94e-04 | 3.03e-03 | 47 |
GO:005196211 | Prostate | Tumor | positive regulation of nervous system development | 69/3246 | 272/18723 | 4.99e-04 | 3.67e-03 | 69 |
GO:006100112 | Prostate | Tumor | regulation of dendritic spine morphogenesis | 18/3246 | 47/18723 | 5.21e-04 | 3.82e-03 | 18 |
GO:012003412 | Prostate | Tumor | positive regulation of plasma membrane bounded cell projection assembly | 32/3246 | 105/18723 | 6.58e-04 | 4.66e-03 | 32 |
GO:006099711 | Prostate | Tumor | dendritic spine morphogenesis | 21/3246 | 61/18723 | 9.70e-04 | 6.30e-03 | 21 |
GO:009917511 | Prostate | Tumor | regulation of postsynapse organization | 28/3246 | 90/18723 | 9.74e-04 | 6.31e-03 | 28 |
GO:001059113 | Prostate | Tumor | regulation of lamellipodium assembly | 16/3246 | 42/18723 | 1.12e-03 | 7.16e-03 | 16 |
GO:005196011 | Prostate | Tumor | regulation of nervous system development | 102/3246 | 443/18723 | 1.20e-03 | 7.60e-03 | 102 |
GO:003300211 | Prostate | Tumor | muscle cell proliferation | 61/3246 | 248/18723 | 2.26e-03 | 1.28e-02 | 61 |
GO:00434033 | Prostate | Tumor | skeletal muscle tissue regeneration | 14/3246 | 37/18723 | 2.43e-03 | 1.36e-02 | 14 |
GO:00148121 | Prostate | Tumor | muscle cell migration | 31/3246 | 110/18723 | 3.15e-03 | 1.65e-02 | 31 |
GO:00609991 | Prostate | Tumor | positive regulation of dendritic spine development | 15/3246 | 42/18723 | 3.32e-03 | 1.73e-02 | 15 |
GO:003003213 | Prostate | Tumor | lamellipodium assembly | 22/3246 | 72/18723 | 4.15e-03 | 2.08e-02 | 22 |
GO:001097611 | Prostate | Tumor | positive regulation of neuron projection development | 42/3246 | 163/18723 | 4.24e-03 | 2.12e-02 | 42 |
GO:006053812 | Prostate | Tumor | skeletal muscle organ development | 42/3246 | 166/18723 | 5.98e-03 | 2.77e-02 | 42 |
GO:004544511 | Prostate | Tumor | myoblast differentiation | 24/3246 | 84/18723 | 7.23e-03 | 3.24e-02 | 24 |
GO:000751713 | Prostate | Tumor | muscle organ development | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RIN1 | SNV | Missense_Mutation | novel | c.1624N>G | p.Leu542Val | p.L542V | Q13671 | protein_coding | tolerated(0.46) | benign(0.19) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
RIN1 | SNV | Missense_Mutation | novel | c.2022N>A | p.Phe674Leu | p.F674L | Q13671 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RIN1 | SNV | Missense_Mutation | | c.73C>G | p.Leu25Val | p.L25V | Q13671 | protein_coding | tolerated_low_confidence(0.1) | benign(0.069) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
RIN1 | SNV | Missense_Mutation | novel | c.1291G>A | p.Val431Ile | p.V431I | Q13671 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
RIN1 | SNV | Missense_Mutation | | c.803N>G | p.Pro268Arg | p.P268R | Q13671 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-D8-A27T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
RIN1 | SNV | Missense_Mutation | rs62619978 | c.2245N>T | p.Arg749Trp | p.R749W | Q13671 | protein_coding | deleterious_low_confidence(0.03) | benign(0.183) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
RIN1 | insertion | Nonsense_Mutation | novel | c.1822_1823insCATAGCTGCATCCAAAAGAGGCCCAGGTCATCTAACCTAAGGAGAAT | p.Arg608ProfsTer2 | p.R608Pfs*2 | Q13671 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
RIN1 | insertion | Frame_Shift_Ins | novel | c.1770_1771insACTTGTTTTTGCTTCTCCTCCTGCATAGCACCTCCTCCGAGTAG | p.Gly591ThrfsTer25 | p.G591Tfs*25 | Q13671 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
RIN1 | insertion | Nonsense_Mutation | novel | c.1770_1771insAATAGGACCTACCTCCTGGGGTTGAGGTGAAGATTAAATG | p.Gly591AsnfsTer10 | p.G591Nfs*10 | Q13671 | protein_coding | | | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
RIN1 | SNV | Missense_Mutation | novel | c.1922N>T | p.Ser641Phe | p.S641F | Q13671 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |